Skip to content
Clinical Trials – home
Incyte Corp.
Sponsor

Incyte Corp.

United States 1801 Augustine Cut Off, 19803-4404, United States

About the sponsor

Incyte Corp. funds research across diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary mediastinal large B-cell lymphoma, and other hematologic malignancies, with additional interest in myelofibrosis, myeloproliferative neoplasms, and myelodysplastic and overlap syndromes. Its portfolio also includes studies in autoimmune hemolytic anemia, immune-mediated thrombocytopenia, and anaemia associated with myelofibrosis.

  • Diffuse large B-cell lymphoma
  • Myelofibrosis
  • Autoimmune cytopenias

Research also extends to treatment settings involving relapsed or refractory disease and advanced blood cancers requiring ongoing therapeutic options.

About Specializations

Incyte Corp. runs clinical trials in conditions such as Hidradenitis, Vitiligo, Neurodermatitis, Chronic graft versus host disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

48 clinical trials

Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tafasitamab
  • Sponsor:Incyte Corp.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Incb000928
  • Sponsor:Incyte Corp.

Myelofibrosis

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.
Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tafasitamab
  • Sponsor:Incyte Corp.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).